CAJ | 학술논문

目的：探讨中药贞芪扶正胶囊联合同步放化疗治疗晚期非小细胞肺癌（NSCLC）的临床疗效。方法：选择72例晚期非小细胞肺癌患者，分为两组，试验组采用贞芪扶正胶囊加同步放化疗方案，对照组行单纯同步放化疗治疗，对两组的近期疗效和毒副反应进行观察。结果：试验组治疗有效率（CR＋PR）为61.54%，对照组治疗有效率（CR＋PR）为60.61%；两组比较差异无统计学意义（P＝0.95）。对照组出现白细胞减少发生率为87.87%，试验组为53.85%（21/39）。两组比较差异有统计学意义，P<0.05。对照组发生血小板减少的发生率为39.39%（13/33），试验组为20.51%（8/39），差异有统计学意义，P＝0.025。两组均有不同程度的消化道反应，肝、肾功能损伤及神经毒性反应，但差异均无统计学意义。结论：贞芪扶正胶囊能明显改善同步放化疗患者的骨髓抑制，值得在临床上推广。
목적：탐토중약정기부정효낭연합동보방화료치료만기비소세포폐암（NSCLC）적림상료효。방법：선택72례만기비소세포폐암환자，분위량조，시험조채용정기부정효낭가동보방화료방안，대조조행단순동보방화료치료，대량조적근기료효화독부반응진행관찰。결과：시험조치료유효솔（CR＋PR）위61.54%，대조조치료유효솔（CR＋PR）위60.61%；량조비교차이무통계학의의（P＝0.95）。대조조출현백세포감소발생솔위87.87%，시험조위53.85%（21/39）。량조비교차이유통계학의의，P<0.05。대조조발생혈소판감소적발생솔위39.39%（13/33），시험조위20.51%（8/39），차이유통계학의의，P＝0.025。량조균유불동정도적소화도반응，간、신공능손상급신경독성반응，단차이균무통계학의의。결론：정기부정효낭능명현개선동보방화료환자적골수억제，치득재림상상추엄。
Objective: To investigate clinical efficacy of the Zhenqi Fuzheng capsule plus concurrent chemoradiotherapy on advanced NSCLC. Methods: 72 patients were divided into two groups, the treatment was given the Zhenqi Fuzheng capsule plus concurrent chemoradiotherapy, the control group was treated by concurrent chemoradiotherapy. Short-term effects and side reaction were observed in both. Results: The total efficacy in the treatment was 61.54%, 60.61% in the control. The difference was statistically significant (P=0.95). Incidence of aleucocytosis in the control was 87.87%, 53.85% in the treatment. The difference was statistically significant (P<0.05). Incidence of thrombocytopenia in the control was 39.39%, 20.51% in the treatment. The difference was statistically significant (P=0.025). There were different degrees of gastrointestinal reaetion, impairment of liver and kidney and neurotoxicity, but there were no statistically significance. Conclusion: The Zhenqi Fuzheng capsule could improve myelosuppression in concurrent chemoradiotherapy, and was worthy of clinical promotion.